Phillip Henderson, DO
Gastroenterology · Mobile, ALNPI 1144450792
Payments from drug & device makers
Across 592 payments — averaging $779.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$145K
- Madrigal Pharmaceuticals$132K
- AbbVie$111K
- Intercept Pharmaceuticals, Inc.$53K
- Novo Nordisk$19K
- Takeda Pharmaceuticals U.S.A., Inc.$247
- plus $1K from 16 others
What the payments were for
- Consulting fees$3,4231%
- Speaking & faculty fees$372,78081%
- Travel & lodging$72,45016%
- Food & beverage$12,8383%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 164 | $144,729 |
| Madrigal Pharmaceuticals | 91 | $132,285 |
| AbbVie | 219 | $110,663 |
| Intercept Pharmaceuticals, Inc. | 53 | $53,294 |
| Novo Nordisk | 10 | $19,310 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $247 |
| Covidien LP | 3 | $185 |
| Johnson & Johnson | 8 | $139 |
| Pfizer | 5 | $100 |
| Bristol Myers Squibb | 5 | $98 |
| ERBE USA Inc | 2 | $90 |
| Ferring Pharmaceuticals Inc. | 6 | $88 |
| Mallinckrodt Hospital Products Inc. | 3 | $61 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $60 |
| Fujifilm Wako Diagnostics U.S.A. Corporation | 1 | $50 |
| Nestle Healthcare Nutrition Inc. | 2 | $42 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Echosens North America, Inc. | 1 | $17 |
| VBI Vaccine (delaware) Inc. | 1 | $17 |
| Ardelyx, Inc. | 1 | $15 |
| Celltrion USA Inc. | 1 | $15 |
| Organon | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$461,537 in reported general payments places this provider in the 95th percentile of 225 gastroenterology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 216 | $769,378 |
| VemlidyTenofovir Alafenamide | 31 | $44,145 |
| Everolimus | 32 | $31,876 |
| Ursodiol | 161 | $24,793 |
| LinzessLinaclotide | 35 | $23,166 |
| OzempicSemaglutide | 15 | $16,535 |
| Tenofovir Disoproxil Fumarate | 74 | $10,234 |
| Mycophenolate Mofetil | 109 | $8,548 |
| Tacrolimus | 155 | $8,070 |
| Sucralfate | 25 | $7,783 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 83 | $5,303 |
| Sirolimus | 26 | $5,022 |
| Lactulose | 123 | $3,801 |
| Azathioprine | 75 | $3,086 |
| Nadolol | 49 | $2,627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $60 | $769,378216 claims |
| GileadVemlidy | $144,729 | $44,14531 claims |
| AbbVieLinzess | $110,663 | $23,16635 claims |
| Novo NordiskOzempic | $19,310 | $16,53515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 225 gastroenterology providers in Alabama.
Other gastroenterology in Mobile
- Jonathan SiegelMobile$2.6M
- Charles JohnsonMobile$1.2M
- Jack DipalmaMobile$958K
- William SonnierMobile$178K
- Jorge HerreraMobile$167K
- Matthew EvesMobile$46K
- John KirbyMobile$34K
- Michael SandersMobile$25K
- Cody BarnettMobile$22K
- Susan FleetMobile$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.